Active Trials

These COVID-19 clinical trials are active and approved by Health Canada. Many more are pending approval and will be added in the days and weeks ahead.

Help us complete the circle. Add your trial to our list of active COVID-19 Canadian clinical trials and gain access to a wider participant registry.

Trial name A Double-Blind, Randomized, Placebo-Controlled, Pilot Phase II Study of the Efficacy and Safety of Lau-7B in the Treatment of Adult Hospitalized Patients with COVID-19 Disease
Type of trial Phase II
Trial ID NCT 04417257
Health Canada Status Health Canada approved
Trial Status Open
Location
Quebec
Trial description

This study is for people who are hospitalized with COVID-19 who are at high risk for complications. Study participants will receive either (1) LAU-7b with standard of care, or (2) placebo with standard of care. The study is to see if LAU-7b prevents severe COVID-19 symptoms and death.

Study team
Ramy Saleh
Dr. Ramy Saleh, MD, MSc, FRCPC
Medical Oncologist and researcher
McGill University Health Center
Dr. Todd Lee
Dr. Todd Lee
MD
McGill University Health Center
Trial name A Multi-Centre, Randomized, Blinded, Placebo Controlled Clinical Trial of the Safety and Effectiveness of Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Children
Type of trial Pending
Trial ID No Id
Health Canada Status Health Canada approved
Trial Status Pending
Location
Quebec
Trial description
Study team
Research Institute of the McGill University Health Centre
.
.
Trial name A Randomized, Open-Label Trial of CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness (CONCOR-1)
Type of trial Phase III
Trial ID NCT 04348656
Health Canada Status Health Canada approved
Trial Status Open
Location
Ontario, Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Prince Edward Island, Quebec, Saskatchewan, Northwest Territories, Nunavut, Yukon
Trial description

This study is for people who are hospitalized for COVID-19. All study participants will get convalescent plasma (a part of blood) to see if it prevents death and reduces intubation, and to see whether people are able to leave the intensive care unit and the hospital faster.

Study team
Donald Arnold
Dr. Donald Arnold
MD
McMaster University
Trial name A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia (COVACTA)
Type of trial Phase III
Trial ID NCT 04320615
Health Canada Status Health Canada approved
Trial Status Open
Location
Quebec, Ontario
Trial description

This study compares tocilizumab with placebo in people who are hospitalized with severe COVID-19 to see if tocilizumab improves clinical symptoms.

Study team
Hoffmann-La Roche Limited
.
.
Trial name An Adaptive Phase 3, Randomized, Double-blind, Placebo-controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID19
Type of trial Phase III
Trial ID NCT 04327388
Health Canada Status Health Canada approved
Trial Status Open
Location
Quebec, Ontario, British Columbia
Trial description

This study is for people who are hospitalized with severe or critical COVID-19 infection. The study compares sarilumab and placebo to see if sarilumab prevents death and impoves clinical symptoms of COVID-19.

Study team
Trial name Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) (COVID-19)
Type of trial Phase III
Trial ID NCT 04322682
Health Canada Status Health Canada approved
Trial Status Open
Location
Quebec
Trial description

This study is for people who have COVID-19, who are not admitted in the hospital, and who meet study-related high-risk criteria. The study compares colchicine to placebo to see if colchicine prevents hospitalization or death.

Study team
Dr. Jean-Claude Tardif
Dr. Jean-Claude Tardif
MD
Montreal Heart Institute
Trial name CONCOR-KIDS: A randomized, multicentered, open-label Phase 2 clinical trial of the safety and efficacy of human Coronavirus-immune convalescent plasma for the treatment of COVID-19 disease in hospitalized children
Type of trial Phase II
Trial ID NCT04377568
Health Canada Status Health Canada approved
Trial Status Pending
Location
Alberta, British Columbia, Manitoba, Nova Scotia, Ontario, Quebec, Saskatchewan
Trial description

This study is for children hospitalized with COVID-19. Study participants will know which therapy they receive, and it will be either (1) standard of care, or (2) convalescent plasma and standard of care. The study is to see if convalescent plasma improves clinical symptoms of COVID-19 and to see if it prevents death.

Study team
Dr. Julia Upton
Dr. Julia Upton
MD, MPH, Study Chair
Allergy and Immunology Department, The Hospital for Sick Children
Trial name Lessening Organ Dysfunction With Vitamin C (LOVIT)
Type of trial Phase III
Trial ID NCT 03680274
Health Canada Status Health Canada approved
Trial Status Open
Location
Quebec
Trial description

This study is for patients who are hospitalized in the intensive care unit for COVID-19. The study compares high-dose Vitamin C with placebo to see if Vitamin C prevents sepsis, and therefore prevents death or persistent organ dysfunction.

Study team
Dr. Francois Lamontagne
Dr. Francois Lamontagne
MD
Centre Hospitalier de l'Université de Sherbrooke
Dr. Neill Adhikari
Dr. Neill Adhikari
MDCM, FRCPC, MSc
Sunnybrook Health Sciences Centre, University of Toronto
Trial name Mild - CONTAIN Ciclesonide Clinical Trial COVID-19 Treatment
Type of trial Pending
Trial ID No Id
Health Canada Status Health Canada approved
Trial Status Pending
Location
Quebec
Trial description
Study team
Research Institute of the McGill University Health Centre
.
.
Trial name Multi-Center, Randomized, Controlled, Phase II Clinical Efficacy Study Evaluating Nitric Oxide Releasing Solution (NORS) Treatment for the Prevention and Treatment of COVID-19 in Healthcare Workers and Individuals at Risk of Infection
Type of trial Phase II
Trial ID NCT 04337918
Health Canada Status Health Canada approved
Trial Status Open
Location
British Columbia, Quebec
Trial description

This study is for people who work or live with patients who have COVID-19, or who work in places that have high risk of contact with patients who have COVID-19. Study participants will either (1) take standard precautions, or (2) take standard precautions and Nitric Oxide Releasing Solution (NORS) to see if NORS prevents COVID-19 infection. Study participants who become COVID-19 positive will take NORS to see if it reduces hospitalization, oxygen therapy, or the need for machines to help with breathing.

Study team
Dr. Jeremy Road
Dr. Jeremy Road
MD
BC Diabetes
Trial name Post-exposure Prophylaxis (PEP) or Preemptive Therapy for COVID-19: A Pragmatic Randomized Clinical Trial
Type of trial Phase III
Trial ID NCT 04308668
Health Canada Status Health Canada approved
Trial Status Open
Location
Quebec, Manitoba, Alberta, Ontario
Trial description

This study tests whether hydroxychloroquine can (1) prevent COVID-19 after someone has been exposed to SARS-CoV-2 coronavirus, and (2) prevent hospitalizations and severe symptoms in people who have tested positive for COVID-19. People in the study with take hydroxychloroquine or a placebo.

Study team
Todd C. Lee
Todd C. Lee, MD, MPH, FIDSA
Associate Professor in the Department of Medicine
McGill University
Ryan Zarychanski
Ryan Zarychanski
MD
University of Manitoba
Lauren E. Kelly
Lauren E. Kelly, PhD, MSc, CCRP
Clinical Trialist and Certified Clinical Research Professional with SoCRA
Organization
IIan Schwartz
IIan Schwartz
MD
University of Alberta
Emily McDonald
Emily McDonald, MD, MSc, FRCPC
Assistant Professor of Medicine
Organization
Dr. Zain Chagla
Dr. Zain Chagla
MD MSc FRCPC DTMH
McMaster University
Trial name Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (REMAP-CAP)
Type of trial Phase IV
Trial ID NCT 02735707
Health Canada Status Health Canada approved
Trial Status Open
Location
Ontario, Quebec
Trial description

This study is for people who are hospitalized in the intensive care unit for COVID-19. The study measures whether different treatments and combinations of treatments will prevent death.

Study team
Dr. John Marshall
Dr. John Marshall
MD
Director, Critical Care Research, St. Michael’s Hospital, Unity Health
Dr. Deborah Cook
Dr. Deborah Cook
MD
St. Joseph's Healthcare Hamilton
Dr. Francois Lamontagne
Dr. Francois Lamontagne
MD
Centre Hospitalier de l'Université de Sherbrooke
Trial name Therapeutic-dose anti-coagulation for the treatment of hospitalized patients with COVID-19: the antthrombotic therapy to ameliorate complications of COVID01 (ATTACC) trial
Type of trial Phase II | Phase III
Trial ID NCT04372589
Health Canada Status Health Canada approved
Trial Status Open
Location
British Columbia, Manitoba, Ontario, Quebec, Saskatchewan
Trial description

This study is for people who are hospitalized for COVID-19. Study participants will receive heparin or usual care, to see if heparin prevents the need for a machine to help with breathing or death.

Study team
Dr. Patrick Lawler
Dr. Patrick Lawler
MD, MPH
Peter Munk Cardiac Centre/University Health Network
Dr. Ewan Goligher
Dr. Ewan Goligher
MD, PhD
University Health Network, Toronto
Dr. Ryan Zarychanski
Dr. Ryan Zarychanski
MD, MSc, FRCPC
University of Manitoba
Trial name Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial (CATCO)
Type of trial Phase II
Trial ID NCT 04330690
Health Canada Status Health Canada approved
Trial Status Open
Location
Alberta, British Columbia, Ontario, Quebec
Trial description

This study is for people who are admitted in the hospital with COVID-19. The study compares 4 different treatments to prevent death and improve clinical symptoms. The study participants will know which treatment they are getting, which will be one of: (1) standard care, (2) lopinavir/ritonavir with standard care, (3) hydroxychloroquine with standard care, or (4) remdesivir with standard care.

Study team
Dr. Nelson Lee
Dr. Nelson Lee
MD
University of Alberta Hospital
Dr. Allison Mah
Dr. Allison Mah
MD
Vancouver General Hospital,
Dr. Natasha Press
Dr. Natasha Press
MD
St. Paul’s Hospital
Dr. Shane English
Dr. Shane English
MD
The Ottawa Hospital
Dr. Robert Fowler
Dr. Robert Fowler
MD
Sunnybrook Health Sciences Centre
Dr. Bryan Coburn
Dr. Bryan Coburn
MD
Toronto Western Hospital
Dr. Matthew Cheng
Dr. Matthew Cheng
MD
McGill University Health Centre-Glen Site Royal Victoria HospitalRecruiting
Dr. Alexis Turgeon
Dr. Alexis Turgeon
MD
CHU de Québec – Université Laval
Dr. Francois Lellouche
Dr. Francois Lellouche
MD
Institut Universitaire de Cardiologie et de Pneumologie de Québec- Université Laval
Dr. Daniel Ovekim
Dr. Daniel Ovekim
MD
Royal Jubilee Hospital
Dr. Anna Geagea
Dr. Anna Geagea
MD
North York General Hospital
Dr. Francois Lamontagne
Dr. Francois Lamontagne
MD
Centre Hospitalier de l'Université de Sherbrooke